PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
10.36%
Revenue growth similar to ADI's 10.55%. Walter Schloss would see if both companies share industry tailwinds.
17.05%
Gross profit growth 1.25-1.5x ADI's 12.13%. Bruce Berkowitz would see if strategic sourcing or brand premium explains outperformance.
41.52%
EBIT growth above 1.5x ADI's 22.71%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
42.32%
Operating income growth above 1.5x ADI's 22.71%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
40.25%
Net income growth above 1.5x ADI's 22.84%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
43.18%
EPS growth above 1.5x ADI's 22.45%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
40.91%
Diluted EPS growth above 1.5x ADI's 22.92%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.93%
Share reduction while ADI is at 0.38%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.91%
Reduced diluted shares while ADI is at 0.10%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
0.31%
Dividend growth under 50% of ADI's 8.80%. Michael Burry might suspect more pressing needs for cash or weaker earnings power.
67.75%
OCF growth 1.25-1.5x ADI's 51.41%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
80.52%
FCF growth similar to ADI's 77.75%. Walter Schloss would attribute it to parallel capital spending and operational models.
67.30%
10Y revenue/share CAGR above 1.5x ADI's 22.40%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
58.50%
5Y revenue/share CAGR above 1.5x ADI's 35.91%. David Dodd would look for consistent product or market expansions fueling outperformance.
2.76%
Positive 3Y CAGR while ADI is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.
152.27%
10Y OCF/share CAGR above 1.5x ADI's 20.55%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
64.60%
Below 50% of ADI's 191.45%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
32.57%
3Y OCF/share CAGR above 1.5x ADI's 16.00%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
155.09%
Net income/share CAGR above 1.5x ADI's 46.89% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
210.77%
5Y net income/share CAGR at 75-90% of ADI's 236.44%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
9.70%
Positive short-term CAGR while ADI is negative. John Neff would see a clear advantage in near-term profit trajectory.
38.59%
10Y equity/share CAGR at 50-75% of ADI's 63.86%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
34.39%
Below 50% of ADI's 89.29%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
3.61%
Below 50% of ADI's 31.72%. Michael Burry suspects a serious short-term disadvantage in building book value.
1337.84%
10Y dividend/share CAGR above 1.5x ADI's 823.78%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
174.90%
5Y dividend/share CAGR above 1.5x ADI's 84.95%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
132.42%
3Y dividend/share CAGR above 1.5x ADI's 67.86%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
12.69%
AR growth well above ADI's 9.75%. Michael Burry fears inflated revenue or higher default risk in the near future.
1.75%
Inventory growth well above ADI's 2.93%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-5.94%
Negative asset growth while ADI invests at 3.05%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-0.53%
We have a declining book value while ADI shows 2.44%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-17.76%
We’re deleveraging while ADI stands at 0.02%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-4.64%
Our R&D shrinks while ADI invests at 5.92%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.46%
We cut SG&A while ADI invests at 3.98%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.